Xolair (omalizumab) - Roche, Novartis
Dupixent (dupilumab) - Sanofi, Regeneron
Impact Of Baseline Immunoglobulin E On Response To Omalizumab Versus Dupilumab In Chronic Spontaneous Urticaria (ACAAI 2026) - Oct 28, 2026 - Abstract #R090; Pres time: Nov 13, 2026; 04:20 PM - 06:00 PM; Location: Phoenix Convention Center • North Halls 4–6 (Lower Level); Monitor 18; No abstract available 
Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
https://annualmeeting.acaai.org/2026/submit_abstract.cfm
 
Oct 28, 2026
 
Prev Next